Search results
Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?
Zacks via Yahoo Finance· 2 months agoTakeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects,...
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Motley Fool· 9 months agoIf you're looking for a high-yield dividend stock in the healthcare sector, you might be interested...
Got $5,000? These 2 Dividend Stocks Haven't Been This Cheap in Years
Motley Fool· 2 years agoWhen dividend stocks dip in price and go on sale, they can create buying opportunities for long-term...
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Zacks via Yahoo Finance· 9 months agoHere at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and...
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
Barrons.com· 1 month ago13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds...
One Ultra-Cheap High-Yield Dividend Stock to Buy
Motley Fool via Yahoo Finance· 5 months agoDividend stocks that trade at cheap valuations can give investors multiple ways to profit from them. In addition to dividend income, you're also...
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
Motley Fool· 2 years agoOne happy consequence of a bear market is that dividend yields rise as stock prices fall. Three...
With 47% ownership, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has piqued the interest of...
Simply Wall St. via Yahoo Finance· 4 months agoKey Insights Given the large stake in the stock by institutions, Phathom Pharmaceuticals' stock...
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Zacks via Yahoo Finance· 5 months agoHere at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and...
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd's (NYSE: TAK) Phase 3 PhALLCON trial of Iclusig (ponatinib) met its...